February 14, 2019
It might mean swapping out fluorescent light bulbs, implementing a flexible work schedule, or providing a dark room where staff can recover from migraine attacks.
February 12, 2019
A Trump administration proposal designed to cut prescription drug costs could actually see some seniors paying $2,000 more each month out of their own pockets, a new study published in the Journal of the American Medical Association suggests.
February 8, 2019
More than 50 percent of Europeans have raised cholesterol, increasing their risk of heart attack, stroke and death – and costing the EU billions every year in health care expenses and lost productivity. So explains a new “Fast Facts” policy brief from the European Alliance for Patient Access, a division of the Global Alliance for Patient Access.
February 7, 2019
Has the era of lower out-of-pocket drug prices finally arrived?
February 5, 2019
New survey data reveals that stigma, lack of awareness and misinformation may hinder treatment for gout, a chronic disease characterized by sudden and excruciating attacks. The national poll, conducted by Alliance for Gout Awareness, surveyed 169 gout patients across the country about their experiences with the disease and their beliefs about treatment.
February 1, 2019
Monthly subscription for streaming music? Sure. Unlimited gym access? Of course. Favorite Netflix shows? Yep. But hepatitis C treatment by subscription?
Maybe so.
January 31, 2019
England has a plan. It’s comprehensive, long term and aimed at preventing 150,000 heart attacks and strokes over the next 10 years. How? By, among other measures, reducing high cholesterol, hypertension and atrial fibrillation.
January 25, 2019
“Important Prescription Plan Change,” the letter announced. “We’re writing to inform you of an important upcoming change to your specialty prescription benefits.”
January 22, 2019
A darling of Hollywood’s movie awards season is inviting discussion on an unexpected topic: gout.
January 17, 2019
An incomplete and poorly conceived report from the controversial Institute for Clinical and Economic Review has set its sights on a most unbecoming target: infants with a degenerative, life-threatening neurological condition.
